OCUGEN, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
OCUGEN, INC. (OCGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $824.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $484.00K, a 332.14% increase year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $340.00K.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $17.00K.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $75.00K, a 18.48% decline year-over-year.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $204.00K, a 11.48% increase from fiscal 2024.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $183.00K, a 8.93% increase from fiscal 2023.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $168.00K.
- OCUGEN, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $484.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $824.00K 10-Q · filed 2026-08-06 | $841.00K derived: sum of 3 quarters · filed 2026-08-06 | $916.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $340.00K 10-Q · filed 2026-05-08 | $357.00K derived: sum of 2 quarters · filed 2026-05-08 | $432.00K derived: sum of 3 quarters · filed 2026-05-08 | $544.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $92.00K derived: sum of 2 quarters · filed 2026-03-04 | $204.00K derived: sum of 3 quarters · filed 2026-03-04 | $204.00K 10-K · filed 2026-03-04 |
| 2025-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $187.00K derived: sum of 2 quarters · filed 2025-11-05 | $187.00K 10-Q · filed 2025-11-05 | $187.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | $112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $112.00K 10-Q · filed 2025-08-04 | $112.00K derived: sum of 3 quarters · filed 2025-08-04 | $204.00K derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-05-09 | $92.00K derived: sum of 3 quarters · filed 2025-05-09 | $139.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $92.00K derived: sum of 2 quarters · filed 2025-03-05 | $139.00K derived: sum of 3 quarters · filed 2025-03-05 | $183.00K 10-K · filed 2025-03-05 |
| 2024-09-30 | $92.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $139.00K derived: sum of 2 quarters · filed 2024-11-14 | $183.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $91.00K 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $44.00K 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $168.00K 10-K · filed 2024-04-16 | |||
| 2021-09-30 | $1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $8.04M 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | $6.44M 10-Q · filed 2021-08-06 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-03-22 | |||
| 2017-12-31 | $8.00K 10-K · filed 2019-03-22 | |||
| 2016-12-31 | $10.00K 10-K · filed 2018-03-15 | |||
| 2015-12-31 | $300.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |